Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 16, 2021 at 10:42 PM.

  1. #1 cafead, Mar 16, 2021 at 10:42 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Long-term data from Janssen’s Phase III DISCOVER-2a trial show that TREMFYA® (guselkumab), a selective IL-23 inhibitor, lead to skin clearance and joint symptom relief for up to two years in patients with active psoriatic arthritis (PsA).

    article source
     
    Quote

Reply to Thread